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ABSTRACT 
The objective of this work was to prepare biodegradable sustained release parenteral 
microspheres of NNDMA-curcumin (NNDMAC), a novel curcumin analogue, characterize the 
formulation and evaluate the hepatoprotective activity of the microsphere formulation. 
Microspheres were prepared using solvent evaporation technique using polycaprolactone and 
were further characterized for various parameters. In vivo animal studies for 10 days were carried 
out for the determination of hepatoprotective activity of the formulation in a CCl4 model. 
Particles of 12 µm size with 75.41% yield with no drug-polymer interaction were obtained. The 
drug release was sustained for 10 days. Significant hepatoprotection which was better than 
repeated I.V. administration was offered by the microsphere formulation in this 10-day study. 
Prepared NNDMAC microspheres have potential use in liver toxicity/cirrhosis. 
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INTRODUCTION 
Liver disease is defined as any change in the anatomy or function of the liver. Liver is 
one of the major organs of the body which has tremendous capacity to detoxify toxic principle 
and synthesize useful principles. Thus, damage to liver can affect our body tremendously. 
Various types of liver disorders such as cirrhosis, jaundice, tumors, metabolic and degenerative 
lesions, liver cell necrosis and hepatitis etc exist1. Liver disorders can result from viruses, 
xenobiotics, excessive drug therapy, environmental pollution and alcohol intoxication. The 
management of liver diseases is still a challenge to the modern medicine. Few treatments exist in 
modern allopathy. Thus, drug discovery for these diseases is the need of the hour. Curcumin, an 
ayurvedic natural product previously demonstrated hepatoprotective activity2. Similarly, another 
curcumin analog BDMCA also demonstrated significant hepatoprotective activity which was 
higher than compared to that of curcumin3.   In the continuation of quest for new drugs in liver 
disorders, we synthesized a series of curcumin analogs. These analogs demonstrated better 
hepatoprotective activity as well as antidepressant activity when compared to that of curcumin 
(4). This can be attributed to better pharmacokinetics, stability and low metabolism. In this study, 
we investigated a delivery approach to one of these curcumin analogs, 
NNdimethyaminocurcumin (NNDMAC). The structure of NNDMAC is shown in Figure 1. 
Sustained release parenteral formulations offer better pharmacokinetics to the drug compared to 
the conventional formulation thereby improves the activity. In this study, we compared the 
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study with an equivalent parenteral I.V. formulation. Advantages with such parenteral sustained 
release delivery systems were previously reported5, 6. The results of hepatoprotective activity of 
the molecule will be better clarified using a delivery system approach when compared to the 
administration in a solution form. Thus, the objective of this study was to prepare a sustained 
release parenteral depot for NNDMAC, characterize the formulation and evaluate its 
hepatoprotective activity.   
 
MATERIALS AND METHODS 
The required aromatic aldehyde p N N dimethylamino benzaldehyde was obtained from 
Merck. All the solvents and accessories used in the synthesis of the compound were procured 
from standard sources. Polycaprolactone was purchased from Sigma-aldrich, Germany. Ethanol 
LR, ethyl acetate, tween 80 and dichloromethane were procured from Finar reagents. To conduct 
in vitro drug release studies, magnetic stirrer and cyclo mixer from Remi Equipments Pvt. 
Limited were used. A SL 164 Elico Double Beam UV-Vis Spectrophotometer was used to 
analyze the samples. HPLC from Cyberlabs was used for analysis of synthesized compound. 
Male Wister rats (100 to 150 gms, 5 to 6 weeks old) purchased from animal center of Mahaveera 
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Synthesis of NNDMAC 
A mixture of acetyl acetone (0.01 mole), p N N dimethyl benzaldehyde (0.02 moles), 
boric acid (0.01 mole), dimethyl formamide (10 ml), few drops of diethanolamine and acetic acid 
mixture were refluxed in a mantel for 16 hours at 1500C temperature in a round bottom flask. 
The reaction was monitored by TLC for the confirmation of the formation product. After 
refluxing the reaction mixture was poured into a 10% acetic acid solution and stirred for one 
hour to get a solid mass which was filtered and washed with water to get crude drug. This crude 
drug was purified and separated by column chromatography using 60-120 mesh TLC grade silica 
gel. Purification of the compound was done by using column chromatography.  
 
The column was filled with silica gel of mesh size 60 to 120 and wet packing method was 
followed. The reaction product mixed with silica gel was loaded on top of the column and 
column was run with a mixture of n hexane and ethyl acetate (75:25) of 500 ml volume. The 
pure product was subsequently eluted by running the column with a mixture of methanol and 
benzene (50:50). The elutant was allowed to air dry. It was recrystallized by subsequent 
solubilization in benzene followed by methanol to get pure product. The purity of the compound 
obtained was determined using a HPLC. A HPLC procedure employing a C-18, 100 X 4.6 
column, SPD-10A UV-Vis detector, LC-10 AD pump and C-R7A Plus integrator was used.  
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Fabrication of NNDMAC Microspheres 
Microspheres of NNDMAC using biodegradable polycaprolactone as the polymer were 
prepared by emulsion-solvent evaporation method. Dichloromethane was taken as organic phase 
in which polymer (400mg) and drug (200mg) in a ratio of 2:1 were dissolved (20ml). This 
organic phase was added to the aqueous phase containing tween 80 as surface active agent (1% 
w/v solution) drop by drop while the aqueous phase was kept for stirring on a magnetic stirrer. 
Stirring was continued till complete evaporation of dichloromethane occurred. As the organic 
phase evaporates precipitation of the polymer and drug occurs due to which drug gets entrapped 
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A       B 
         
 
Figure 1: Microscopic view of NNDMAC microspheres 
A) NNDMAC Microspheres under 10x          B) NNDMAC Microspheres under 40X 
 
Characterization of Microspheres 
Percentage Yield:  
It is the ratio of the practical yield to the theoretical yield and was calculated using the formula 
       Practical yield 
Percentage Yield =      ---------------------------------X 100 
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Particle Size Analysis:  
Particle size was determined using optical microscope. Size of 50 particles was taken and 
the average was reported.  
Entrapment Efficiency:  
High performance liquid chromatographic analysis was used for estimation of entrapment 
efficiency. HPLC method was as previously mentioned.  Briefly, 10 mg of the microspheres 
were dissolved in 1 ml of chloroform and 20 µl of the solution was injected into the HPLC and 
the presence of the drug was determined. 
 
In vitro Drug Release Studies:  
A dialysis membrane was used for the release study. The dissolution medium, PBS (7 ml) 
was taken into the receiver compartment. The donor compartment was immersed into the 
receiver compartment so that the edge just touches the receiver compartment.  A 100mg of the 
micro particles were dispersed in 2 ml of distilled water and placed in the donor compartment. 
The rpm of the system was maintained by using magnetic stirrer and bead. Samples (1 ml) were 
removed from the receptor compartment and replaced with fresh medium immediately. The 
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Drug-Excipients Compatibility study:  
This was carried out by FTIR analysis of pure drug (NNDMAC), pure polymer 
(Polycaprolactone), drug loaded microparticles and placebo microparticles (polycaprolactone 
microspheres). 
Evaluation of Hepatoprotective Activity of NNDMAC Microspheres 
The study was carried out on male Wister rats weighing 100-150gms. The animals were 
housed in clean cages and maintained in controlled temperature. They were fed with standard 
diet and ad libitum. Animals were divided into 3 groups each group containing 4 rats. 
Group I: Served as normal control and received normal saline solution orally. 
Group II: Served as toxic control and was given 0.7 ml/kg of carbon tetrachloride (25 ml in 75 
ml olive oil) intraperitonially every third day. 
Group III: Administered NNDMAC micro particular suspension at a dose of 100mg/ml to each 
rat on day 1 of the study.  
For pharmacodynamics group II and group III were give carbon tetrachloride (25% v/v in olive 
oil) after every 3 days. On day 10 the rats were sacrificed and blood was collected. Serum was 
separated by centrifugation and used for the estimation of biochemical parameters such as SGOT 
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formalin solution and stored for histopathological studies. After embedding in paraffin wax, thin 
sections of 5 µm thickness of liver tissue were cut and stained with haemotoxylin-eosin stain. 
Processing of liver tissue: 
 Liver tissues were taken out from fixing solution and dehydrated for 30 minutes each in 
30, 50, 70, 90 and 100% alcohol successively to remove the alcohol from the dehydrated tissue , 
they were kept for 30 minutes each in alcohol: xylene (1:1) followed by pure xylene. The tissues 
were then kept in xylene: paraffin wax mixture (1:1) for 1 hour and then in molten paraffin wax 
at 62ºC, after which they were trimmed and mounted on wooden blocks for thin sectioning. Hand 
microtone (Yorco precision rotary microtone model no. YS1114) was used to cut sections of the 
liver tissues of 5 µm thickness. These thin sections of the liver were then stained with eosin 
hematologic stain. The slides were observed under microscope at a magnification of 40X. 
RESULTS AND DISCUSSION 
NNDMAC was prepared by condensation of p N N dimethyl amino benzaldehyde with 
acetyl acetone in presence of boric acid. Final product obtained after purification by column 
chromatography and recrystallization with benzene and methanol was fine brownish-yellow 
coloured powder. Total yield was found to be 83.68±6.33%. Melting point of the pure compound 
was 134±30C. Percentage purity estimated by HPLC in water: methanol as the mobile phase with 
retention time of 14.23 minutes was 99.845%. The NNDMAC microspheres prepared by 
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average particle size of 20+/-5 µm (Figure 2). The percentage yield of the microspheres was 
65.88+/-9.55%. Entrapment efficiency estimated by HPLC analysis was found to be 22+/-0.84%. 
NNDMAC was found to be compatible with the polymer in the microparticular 
formulation. This compatibility was concluded by comparing the FTIR profiles of pure polymer, 
pure drug, placebo biodegradable microparticles and NNDMAC biodegradable polycaprolactone 
microspheres. From the graphs (Figure 3) it was clear that there is no interaction between the 
drug NNDMAC and polymer polycaprolactone at the end of the fabrication of microspheres. In 
vitro drug release from the NNDMAC microspheres was carried out by dialysis membrane 
technique. The data (Figure 4) indicated that the release of the drug was prolonged for 10 days. 
For estimation of hepatoprotective activity at the end of 10 days, the administration of CCl4 to 
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Figure 2 D. FTIR profiles of NNDMAC microspheres 
Treatment with 100 mg dose of microspheres containing 20mg of NNDMAC intraperitonially 
reversed the elevation of the liver enzymes found in CCl4 treated mice. Histological profile of the 
control animals showed normal hepatic architecture with distinct hepatic cells, well presented 
cytoplasm sinusoidal spaces and central vein (Figure 5A). Disarrangement of normal cells with 
intense centrilobular necrosis was observed in CCl4 intoxication liver (Figure 5C). The 20 mg of 
intraperitonial NNDMAC microspheres exhibited a significant liver protection against CCl4 
induced liver damage, as evidenced by the presence of normal hepatic cords and well defined 















































































B) NNDMAC  Microparticular System 
 
C) CCl4 Toxic Control 
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Drug and Dose ROA SGOT U/L SGPT U/L 
Saline 
Control 
Normal Saline, 1ml/rat Oral 18.66±0.62 8.85±0.88 
IP MS 
NNDMAC microspheres in normal saline, 
equivalent to 100mg/kg of NNDMAC 
+ 
CCl4, 0.7ml/kg, 25%v/v in olive oil 
IP 19.99±0.92 9.52±0.93 
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